**New Treatment Option for Children and Adolescents with Type 1 Diabetes** Afrezza, an inhaled insulin, has been approved by the FDA for children and adolescents. Our clinic is excited to offer this new treatment option to our patients.
**New Treatment Option for Children and Adolescents with Type 1 Diabetes**Afrezza, an inhaled insulin, has been approved by the FDA for children and adolescents. Our clinic is excited to offer this new treatment option to our patients.
Taisie Seigrist, a 15-year-old patient of ours, participated in the clinical trial for Afrezza and experienced life-changing results. When Taisie was 10 years old, she was diagnosed with type 1 diabetes after experiencing persistent thirst and frequent urination.
Managing Type 1 Diabetes
At first, Taisie relied on mealtime injected insulin shots, which were administered as often as seven times per day. However, this treatment option had its challenges. The injections were painful, especially when done in the same location multiple times. They also affected her quality of life, making it difficult for her to participate in school and extracurricular activities.
Managing type 1 diabetes can be emotionally taxing as well. Children and adolescents with diabetes often face stigma and embarrassment associated with injection administration in front of peers.
A New Hope: Afrezza
In 2024, Taisie's endocrinologist asked her to participate in a clinical trial for Afrezza, an inhaled mealtime insulin. This new treatment option has revolutionized Taisie's life, providing her with a needle-free alternative to traditional injections.
Afrezza is an exciting development in the management of type 1 diabetes. If you or your child are struggling with traditional injection therapy, we encourage you to speak with our healthcare team about this new treatment option.
Learn more about hair transplant at Rubenhair clinic.
Get a Free Consultation
Consult with our specialists about FUE procedure, PRP therapy or hair transplant.
